Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INSM
CUSIPN/A
Phone908-977-9900
Debt
Debt-to-Equity Ratio0.70
Current Ratio20.01
Quick Ratio20.01
Price-To-Earnings
Trailing P/E Ratio-8.71
Forward P/E Ratio-6.12
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book5.39
Profitability
EPS (Most Recent Fiscal Year)($2.89)
Net Income$-192,640,000.00
Net MarginsN/A
Return on Equity-68.14%
Return on Assets-46.47%
Miscellaneous
Employees214
Outstanding Shares76,620,000
Market Cap$1,933.97
Insmed (NASDAQ:INSM) Frequently Asked Questions
What is Insmed's stock symbol?
Insmed trades on the NASDAQ under the ticker symbol "INSM."
How were Insmed's earnings last quarter?
Insmed Incorporated (NASDAQ:INSM) released its quarterly earnings results on Wednesday, May, 2nd. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.07. View Insmed's Earnings History.
What price target have analysts set for INSM?
8 equities research analysts have issued twelve-month target prices for Insmed's stock. Their predictions range from $31.00 to $54.00. On average, they anticipate Insmed's stock price to reach $40.00 in the next year. This suggests a possible upside of 57.4% from the stock's current price. View Analyst Ratings for Insmed.
What is the consensus analysts' recommendation for Insmed?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Insmed's key competitors?
Some companies that are related to Insmed include Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH) and Madrigal Pharmaceuticals (MDGL).
Who are Insmed's key executives?
Insmed's management team includes the folowing people:
- Mr. William H. Lewis, Pres, CEO & Director (Age 49)
- Ms. Christine A. Pellizzari, Chief Legal Officer (Age 50)
- Mr. Roger Adsett, Chief Commercial Officer (Age 49)
- Dr. Paul Streck, Chief Medical Officer (Age 55)
- Mr. Paolo Tombesi, Chief Financial Officer (Age 54)
Has Insmed been receiving favorable news coverage?
News headlines about INSM stock have been trending very positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Insmed earned a news sentiment score of 0.55 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.23 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Insmed's major shareholders?
Insmed's stock is owned by many different of institutional and retail investors. Top institutional investors include Fox Run Management L.L.C. (0.03%). Company insiders that own Insmed stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Myrtle S Potter and Orlov S Nicole Schaeffer. View Institutional Ownership Trends for Insmed.
Which institutional investors are buying Insmed stock?
How do I buy shares of Insmed?
Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insmed's stock price today?
One share of INSM stock can currently be purchased for approximately $25.41.
How big of a company is Insmed?
Insmed has a market capitalization of $1.93 billion. The biopharmaceutical company earns $-192,640,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Insmed employs 214 workers across the globe.
How can I contact Insmed?
Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]
MarketBeat Community Rating for Insmed (NASDAQ INSM)
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
